Novavax NVAX, +5.24% stands out as a stark reminder of the biotech sector’s faltering steps in 2023. Once renowned for its Nuvaxovid COVID-19 vaccine,...
Emerging market central banks responded quicker to inflation and remain in better shape financially than developed markets, and EM bonds may add resilience to...